Illumina and Qiagen Enter 15-Year Diagnostics Partnership
Two leaders in genomics and molecular analysis, Illumina and QIAGEN, have announced a 15-year partnership that the companies say is aimed at increasing the...
![Centogene’s CentoMD® rare disease variant database will be integrated into Qiagen’s bioinformatics suite in a rare disease bioinformatics collaboration by the companies. [Source: alengo/Getty]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1291-218x150.jpeg "NIH Commits $38M to Rare Disease Research and Affiliated Data Center")
NIH Commits $38M to Rare Disease Research and Affiliated Data Center
About $31 million in grants has been awarded by The National Institutes of Health in fiscal year 2019 to 20 teams in order to...
Takeda, Prometheus Enter IBD Drug-Companion Diagnostic Partnership
Prometheus Biosciences said its bioinformatics platform and advanced machine learning techniques will be used by Takeda Pharmaceutical as part of a global collaboration to...
Gut Immune Cell Clock Genes Disruption Linked to IBD, Immune Control
Two independent sets of research published in Science Immunology have demonstrated how a subset of immune cells in the gut, known as group 3...
Cepheid’s BCR-ABL Test Gets FDA Approval
Cepheid announced that it has received clearance from the FDA for its Xpert BCR-ABL Ultra for monitoring disease burden in patients with chronic myeloid...
GRAIL’s New Blood-Based Cancer Screening Test Shows High Sensitivity and Specificity
Dana-Farber Cancer Institute researchers report the development of a new blood test that has shown the ability in a multi-center trial to screen for...
Illumina and the Broad Co-Developing Open-Source Secondary Analysis Software
Leading open-source tools, GATK and DRAGEN, are being combined to create a cutting-edge software suite for methods including small variant (SNV) and large variant...
In Conversation with Edward Abrahams, President, the Personalized Medicine Coalition
Edward Abrahams, Ph.D., has been president of the Personalized Medicine Coalition (PMC) since its founding in late 2004. After serving as an anchor partner...
![Researchers at The University of Texas MD Anderson Cancer Center have found that a rare resistance mutation first thought to appear in melanoma (pictured) following treatment with a targeted therapy has instead turned out to be hiding in the tumor all along. [Definiens]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1519-218x150.jpeg "Melanoma Diagnosis Could be More Precise Using miRNA Biomarkers")
Melanoma Diagnosis Could be More Precise Using miRNA Biomarkers
Scientists headed by a team at the University of California, San Francisco (UCSF), now report on a new approach to diagnosing melanoma that uses...
NSIGHT2 Trial Finds No Difference in Diagnostic Rate Between WGS and WES
In a surprising result, a new clinical genomic trial in neonates in the NICU setting found no major difference in the diagnostic rate between...
